Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 4153.TWO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 4153.TWO and 80,000+ other tickers.
See exactly how 4153.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 4153.TWO and 80,000+ other tickers.
DIVA Laboratories, Ltd. specializes in the global provision of advanced display technologies. Its comprehensive product lineup caters to critical environments, including specialized endo/surgical displays designed to render both static and dynamic imagery with precision for hybrid and integrated operating theaters, as well as crucial control room applications. Furthermore, DIVA offers a range of color and monochrome monitors tailored for high-accuracy radiology and broader medical imaging purposes. Beyond healthcare, the company develops interactive touch displays and human-machine interface…
No recent news available.